# An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

> **NCT07020819** · PHASE3 · RECRUITING · sponsor: **Annexon, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Guillain-Barre Syndrome

## Interventions

- **DRUG:** Tanruprubart

## Key facts

- **NCT ID:** NCT07020819
- **Lead sponsor:** Annexon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020819, "An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07020819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*